[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,702,782
  • Shares Outstanding, K 63,066
  • Annual Sales, $ 16,100 K
  • Annual Income, $ -198,970 K
  • EBIT $ -192 M
  • EBITDA $ -177 M
  • 60-Month Beta 0.98
  • Price/Sales 103.62
  • Price/Cash Flow N/A
  • Price/Book 11.07

Options Overview Details

View History
  • Implied Volatility 155.42% (-20.94%)
  • Historical Volatility 102.21%
  • IV Percentile 76%
  • IV Rank 35.87%
  • IV High 302.43% on 02/17/26
  • IV Low 73.19% on 10/03/25
  • Expected Move (DTE 8) 5.31 (20.08%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 3,245
  • Volume Avg (30-Day) 5,287
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 144,092
  • Open Int (30-Day) 129,355
  • Expected Range 21.15 to 31.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.88
  • Number of Estimates 4
  • High Estimate $-0.82
  • Low Estimate $-1.05
  • Prior Year $-0.69
  • Growth Rate Est. (year over year) -27.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.00 +10.25%
on 05/26/26
31.00 -14.65%
on 06/04/26
-1.20 (-4.34%)
since 05/08/26
3-Month
13.21 +100.30%
on 04/10/26
31.00 -14.65%
on 06/04/26
+8.47 (+47.08%)
since 03/09/26
52-Week
8.73 +203.09%
on 03/03/26
71.50 -62.99%
on 10/28/25
+9.56 (+56.57%)
since 06/09/25

Most Recent Stories

More News
UniQure: Q1 Earnings Snapshot

UniQure: Q1 Earnings Snapshot

QURE : 26.46 (-2.00%)
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on...

QURE : 26.46 (-2.00%)
uniQure Reports Tuesday With Regulatory Hope Intact but Financial Runway Shrinking Fast

Barchart Research What to Expect from QURE Earnings QURE Generated May 4, 2026 Current Price $20.68 EPS Estimate $$-0.88 Consensus Rating Moderate Buy Average Move 8.91% uniQure Reports Tuesday With Regulatory...

QURE : 26.46 (-2.00%)
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected  in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential...

QURE : 26.46 (-2.00%)
uniQure to Announce First Quarter 2026 Financial Results

~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, April 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...

QURE : 26.46 (-2.00%)
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their...

QURE : 26.46 (-2.00%)
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

LOS ANGELES , April 12, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE ) for violations...

QURE : 26.46 (-2.00%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , April 12, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure"...

QURE : 26.46 (-2.00%)
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

NEW YORK , April 12, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and...

QURE : 26.46 (-2.00%)
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V. - QURE

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 13, 2026 ...

QURE : 26.46 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 29.27
2nd Resistance Point 28.39
1st Resistance Point 27.42
Last Price 26.46
1st Support Level 25.57
2nd Support Level 24.69
3rd Support Level 23.72

See More

52-Week High 71.50
Fibonacci 61.8% 47.52
Fibonacci 50% 40.11
Fibonacci 38.2% 32.71
Last Price 26.46
52-Week Low 8.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.